Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging
暂无分享,去创建一个
[1] C Crouzel,et al. Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography. , 1986, Circulation.
[2] Robert B. Innis,et al. Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands , 2011, The Journal of Nuclear Medicine.
[3] M. Mattson,et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. , 2003, Journal of neuroscience research.
[4] Julie Price,et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. , 2009, Archives of neurology.
[5] D. Perani,et al. Faculty Opinions recommendation of Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. , 2009 .
[6] R. Raffa,et al. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? , 2011, British journal of clinical pharmacology.
[7] J. Baron,et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment , 2005, Neurocase.
[8] T. Foltynie,et al. Exenatide and the treatment of patients with Parkinson's disease. , 2013, The Journal of clinical investigation.
[9] Technical aspects of amyloid imaging for Alzheimer's disease , 2011, Alzheimer's Research & Therapy.
[10] C. Wiley,et al. The Positron Emission Tomography Ligand DAA1106 Binds With High Affinity to Activated Microglia in Human Neurological Disorders , 2008, Journal of neuropathology and experimental neurology.
[11] H. Engler,et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.
[12] M. Sasaki,et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms , 1996, Journal of the Neurological Sciences.
[13] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[14] K. Herholz. Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer's disease. , 2012, Biomarkers in medicine.
[15] Keith A. Johnson,et al. Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[16] Martin Rossor,et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study , 2008, Neurobiology of Disease.
[17] T. Guilarte,et al. Peripheral benzodiazepine receptor imaging in CNS demyelination: functional implications of anatomical and cellular localization. , 2004, Brain : a journal of neurology.
[18] H. Engler,et al. PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[19] M. Sarazin,et al. Faculty Opinions recommendation of Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. , 2009 .
[20] Roger N Gunn,et al. An 18-kDa Translocator Protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] Roger N Gunn,et al. In-vivo measurement of activated microglia in dementia , 2001, The Lancet.
[22] R. Banati,et al. Visualising microglial activation in vivo , 2002, Glia.
[23] Vijaya L. Melnick,et al. Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.
[24] Christian Hölscher,et al. The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease , 2011, The Journal of Neuroscience.
[25] Nicola Toschi,et al. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. , 2013, The Medical clinics of North America.
[26] N. Greig,et al. Neuroprotective and neurotrophic actions of glucagon‐like peptide‐1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders , 2012, British journal of pharmacology.
[27] D B Calne,et al. Correlation of striatal fluorodopa uptake in the MPTP Monkey with dopaminergic indices , 1993, Annals of neurology.
[28] C. Jack,et al. 11 C PiB and structural MRI provide complementary information in imaging of Alzheimer ’ s disease and amnestic mild cognitive impairment , 2008 .
[29] A. Drzezga,et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[30] Annelaure Damont,et al. Evaluation of the PBR/TSPO Radioligand [18F]DPA-714 in a Rat Model of Focal Cerebral Ischemia , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[31] C. Jack,et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.
[32] A. Kingsbury,et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease , 2008, Journal of Neuroinflammation.
[33] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] Cindee M. Madison,et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI , 2011, Neurobiology of Aging.
[35] Nick C Fox,et al. Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.
[36] Karl Herholz,et al. Evaluation of a Calibrated 18F-FDG PET Score as a Biomarker for Progression in Alzheimer Disease and Mild Cognitive Impairment , 2011, The Journal of Nuclear Medicine.
[37] N. Prins,et al. Amyloid imaging in prodromal Alzheimer's disease , 2011, Alzheimer's Research & Therapy.
[38] David J. Brooks,et al. Imaging biomarkers in Parkinson's disease , 2011, Progress in Neurobiology.
[39] Nick C Fox,et al. Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.
[40] S. Udagawa,et al. Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes. , 2006, Neuroscience research.
[41] C. Hölscher,et al. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease , 2014, Neuropharmacology.
[42] S. Udagawa,et al. Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes , 2006, Neuroscience Research.
[43] H. Kimura,et al. Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels , 1993, Annals of neurology.
[44] C. Jack,et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.
[45] D. Perani,et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. , 2005, Archives of neurology.
[46] Nick C Fox,et al. The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.
[47] Masahiro Fujita,et al. Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker , 2010, NeuroImage.
[48] Sebastien Ourselin,et al. Clinical application of measurement of hippocampal atrophy in degenerative dementias , 2009, Hippocampus.
[49] D. Drucker,et al. Incretin-based therapies for type 2 diabetes mellitus , 2009, Nature Reviews Endocrinology.
[50] M. Mattson,et al. Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron , 2003 .
[51] P. Mcgeer,et al. Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.
[52] R B Banati,et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. , 2000, Brain : a journal of neurology.
[53] C. Jack,et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.
[54] B. Hyman,et al. Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.
[55] Mark E. Schmidt,et al. The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.
[56] G. Bertilsson,et al. Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease , 2008, Journal of neuroscience research.
[57] J O Rinne,et al. Amyloid PET imaging in patients with mild cognitive impairment , 2011, Neurology.
[58] C. Hölscher,et al. Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats , 2013, Neurobiology of Aging.
[59] William E. Klunk,et al. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET , 2009, Neurobiology of Aging.
[60] J. Rinne,et al. Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFT , 2000, Annals of neurology.
[61] W. Jagust,et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.
[62] et al.,et al. Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.
[63] A. Gjedde,et al. Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer´s disease - protocol for a controlled, randomized double-blinded trial. , 2012, Danish medical journal.